CN115710250A - 一种食欲素受体拮抗剂的晶型及其制备方法和用途 - Google Patents

一种食欲素受体拮抗剂的晶型及其制备方法和用途 Download PDF

Info

Publication number
CN115710250A
CN115710250A CN202211397034.XA CN202211397034A CN115710250A CN 115710250 A CN115710250 A CN 115710250A CN 202211397034 A CN202211397034 A CN 202211397034A CN 115710250 A CN115710250 A CN 115710250A
Authority
CN
China
Prior art keywords
crystal form
preparation
compound
present
ray powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211397034.XA
Other languages
English (en)
Chinese (zh)
Inventor
陈敏华
张炎锋
黄春香
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bojian Pharmaceutical Co ltd
Original Assignee
Bojian Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65233118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115710250(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bojian Pharmaceutical Co ltd filed Critical Bojian Pharmaceutical Co ltd
Publication of CN115710250A publication Critical patent/CN115710250A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202211397034.XA 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途 Pending CN115710250A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201710648135 2017-08-01
CN2017106481352 2017-08-01
PCT/CN2018/097797 WO2019024845A1 (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN201880040538.1A CN110799501B (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880040538.1A Division CN110799501B (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Publications (1)

Publication Number Publication Date
CN115710250A true CN115710250A (zh) 2023-02-24

Family

ID=65233118

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211397034.XA Pending CN115710250A (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途
CN201880040538.1A Active CN110799501B (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880040538.1A Active CN110799501B (zh) 2017-08-01 2018-07-31 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Country Status (4)

Country Link
US (1) US10759779B2 (https=)
JP (2) JP7179049B2 (https=)
CN (2) CN115710250A (https=)
WO (1) WO2019024845A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途
JP7489971B2 (ja) * 2019-05-15 2024-05-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 オレキシン－２受容体アンタゴニストの調製において有用な方法及び化合物、及び不純物の少ないＬｅｍｂｏｒｅｘａｎｔ
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
JP7573015B2 (ja) * 2019-09-13 2024-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 不眠症治療用医薬組成物
JP2023506025A (ja) 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス．アール．オー． レンボレキサントの固体形態
MX2022008260A (es) * 2020-01-16 2022-08-04 Eisai R&D Man Co Ltd Sustancia farmacologica de lemborexant y composicion medicinal que la comprende.
CN119285556B (zh) * 2024-12-13 2025-02-28 四川健林药业有限责任公司 莱博雷生中间体的合成纯化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153963A (zh) * 2010-09-22 2013-06-12 卫材R&D管理有限公司 环丙烷化合物
CN104114524A (zh) * 2012-02-17 2014-10-22 卫材R&D管理有限公司 用于食欲肽-2受体拮抗剂的合成的方法和化合物
CN104592184A (zh) * 2014-12-15 2015-05-06 云南省药物研究所 灯盏乙素苷元晶型及其制备方法
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020157A (en) * 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) * 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
CN115710250A (zh) * 2017-08-01 2023-02-24 博健制药有限责任公司 一种食欲素受体拮抗剂的晶型及其制备方法和用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153963A (zh) * 2010-09-22 2013-06-12 卫材R&D管理有限公司 环丙烷化合物
CN104114524A (zh) * 2012-02-17 2014-10-22 卫材R&D管理有限公司 用于食欲肽-2受体拮抗剂的合成的方法和化合物
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia
CN104592184A (zh) * 2014-12-15 2015-05-06 云南省药物研究所 灯盏乙素苷元晶型及其制备方法

Also Published As

Publication number Publication date
CN110799501A (zh) 2020-02-14
JP2020528913A (ja) 2020-10-01
US10759779B2 (en) 2020-09-01
JP7179049B2 (ja) 2022-11-28
US20200190060A1 (en) 2020-06-18
CN110799501B (zh) 2022-11-22
WO2019024845A1 (zh) 2019-02-07
JP2023027066A (ja) 2023-03-01

Similar Documents

Publication Publication Date Title
CN110799501B (zh) 一种食欲素受体拮抗剂的晶型及其制备方法和用途
EP4286377A1 (en) Crystal form of resmetirom, preparation method therefor, and use thereof
WO2019052133A1 (zh) Gsk1278863的晶型及其制备方法和制药用途
EP3812378A1 (en) Crystal form of arn-509, preparation method therefor and use thereof
EP3733666B1 (en) Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
US20220002306A1 (en) Crystal form of upadacitinib and preparation method and use thereof
WO2019019959A1 (zh) 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途
WO2020057622A1 (zh) 卡博替尼苹果酸盐晶型及其制备方法和用途
US20250042866A1 (en) Crystal form of blarcamesine hydrochloride, method for preparing same, and use therof
EP3677575A1 (en) Crystalline form of ozanimod hydrochloride and preparation method therefor
WO2021129467A1 (zh) 一种bms-986165晶型及其制备方法和用途
WO2021143430A1 (zh) 一种bms-986165盐酸盐晶型及其制备方法和用途
WO2024125543A1 (zh) 达洛色替的晶型及其制备方法和用途
EP4056182A1 (en) Crystal form of aprocitentan, preparation method therefor and use thereof
HK40081536A (en) Crystal form of orexin receptor antagonist, preparation method therefor and use thereof
WO2022036782A1 (zh) 一种雄激素受体拮抗剂药物的晶型csvi及其制备方法和用途
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
WO2022105792A1 (zh) 一种喹唑啉酮衍生物的新晶型及其制备方法
WO2019011337A1 (zh) Qaw-039的晶型及其制备方法和用途
WO2022021684A1 (zh) 一种bms-986165盐酸盐晶型csv及其制备方法和用途
HK40092799A (zh) Pn6047盐酸盐的多晶型物
CN116063282A (zh) 奥布替尼化合物的晶型及其制备方法
WO2018130226A1 (zh) 利奥西呱的新晶型及其制备方法和用途
WO2020177705A1 (zh) Filgotinib的马来酸盐晶型CSI及其制备方法和用途
WO2018059420A1 (zh) E52862盐酸盐晶型h及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40081536

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230224

WD01 Invention patent application deemed withdrawn after publication